Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts
Identifieur interne : 000275 ( Main/Corpus ); précédent : 000274; suivant : 000276Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts
Auteurs : Connie Marras ; Michael P. Mcdermott ; Ken Marek ; Paula Rochon ; Gary Naglie ; Caroline M. Tanner ; Alice Rudolph ; Ira Shoulson ; Anthony E. LangSource :
- Movement Disorders [ 0885-3185 ] ; 2011-03.
English descriptors
- KwdEn :
Abstract
The rate of progression of Parkinson's disease (PD) is highly variable. Knowledge of factors associated with disease milestones and commonly used research outcome measures helps with patient counseling and guides the design and interpretation of clinical studies. The objective of the study was to identify prognostic factors for time to acquiring disability requiring dopaminergic therapy that are reproducible within 2 large prospectively followed cohorts. Potential prognostic factors were identified using data from the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) trial, and their reproducibility was examined using data from the Parkinson Research Examination of CEP‐1347 trial (PRECEPT). In multivariable analyses of the DATATOP cohort, higher baseline Unified Parkinson's Disease Rating Scale (UPDRS) scores, full‐time employment, a lesser smoking history, and onset on the left side were associated with a shorter time to disability requiring dopaminergic therapy. PRECEPT data confirmed the associations of higher baseline UPDRS scores and full‐time employment with shorter time to requiring treatment. Any clinical trial using the end point of time to disability requiring dopaminergic therapy should ensure that groups are well balanced with respect to baseline UPDRS scores and the proportion of subjects employed full time and should consider including these variables as covariates in the statistical model for primary analysis of treatment effects. We suspect that individuals employed full time may have a lower threshold for requiring dopaminergic therapy because of occupational demands. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23581
Links to Exploration step
ISTEX:86D7BA3E8F5196138DC85683158DA557FCFD657FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts</title><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name><affiliation><mods:affiliation>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael P." last="Mcdermott">Michael P. Mcdermott</name><affiliation><mods:affiliation>University of Rochester, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Marek, Ken" sort="Marek, Ken" uniqKey="Marek K" first="Ken" last="Marek">Ken Marek</name><affiliation><mods:affiliation>Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA</mods:affiliation></affiliation></author><author><name sortKey="Rochon, Paula" sort="Rochon, Paula" uniqKey="Rochon P" first="Paula" last="Rochon">Paula Rochon</name><affiliation><mods:affiliation>University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Naglie, Gary" sort="Naglie, Gary" uniqKey="Naglie G" first="Gary" last="Naglie">Gary Naglie</name><affiliation><mods:affiliation>University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Toronto Rehabilitation Institute, Toronto, Ontario Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Clinical Decision Making and Health Care, Toronto General Research Institute, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>University Health Network, Divisions of General Internal Medicine and Geriatrics Program, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Rudolph, Alice" sort="Rudolph, Alice" uniqKey="Rudolph A" first="Alice" last="Rudolph">Alice Rudolph</name><affiliation><mods:affiliation>University of Rochester, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name><affiliation><mods:affiliation>University of Rochester, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation><mods:affiliation>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:86D7BA3E8F5196138DC85683158DA557FCFD657F</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23581</idno><idno type="url">https://api.istex.fr/document/86D7BA3E8F5196138DC85683158DA557FCFD657F/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000275</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts</title><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name><affiliation><mods:affiliation>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael P." last="Mcdermott">Michael P. Mcdermott</name><affiliation><mods:affiliation>University of Rochester, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Marek, Ken" sort="Marek, Ken" uniqKey="Marek K" first="Ken" last="Marek">Ken Marek</name><affiliation><mods:affiliation>Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA</mods:affiliation></affiliation></author><author><name sortKey="Rochon, Paula" sort="Rochon, Paula" uniqKey="Rochon P" first="Paula" last="Rochon">Paula Rochon</name><affiliation><mods:affiliation>University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Naglie, Gary" sort="Naglie, Gary" uniqKey="Naglie G" first="Gary" last="Naglie">Gary Naglie</name><affiliation><mods:affiliation>University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Toronto Rehabilitation Institute, Toronto, Ontario Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Clinical Decision Making and Health Care, Toronto General Research Institute, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>University Health Network, Divisions of General Internal Medicine and Geriatrics Program, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Rudolph, Alice" sort="Rudolph, Alice" uniqKey="Rudolph A" first="Alice" last="Rudolph">Alice Rudolph</name><affiliation><mods:affiliation>University of Rochester, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name><affiliation><mods:affiliation>University of Rochester, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation><mods:affiliation>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-03">2011-03</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="608">608</biblScope><biblScope unit="page" to="613">613</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">86D7BA3E8F5196138DC85683158DA557FCFD657F</idno><idno type="DOI">10.1002/mds.23581</idno><idno type="ArticleID">MDS23581</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>prognosis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The rate of progression of Parkinson's disease (PD) is highly variable. Knowledge of factors associated with disease milestones and commonly used research outcome measures helps with patient counseling and guides the design and interpretation of clinical studies. The objective of the study was to identify prognostic factors for time to acquiring disability requiring dopaminergic therapy that are reproducible within 2 large prospectively followed cohorts. Potential prognostic factors were identified using data from the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) trial, and their reproducibility was examined using data from the Parkinson Research Examination of CEP‐1347 trial (PRECEPT). In multivariable analyses of the DATATOP cohort, higher baseline Unified Parkinson's Disease Rating Scale (UPDRS) scores, full‐time employment, a lesser smoking history, and onset on the left side were associated with a shorter time to disability requiring dopaminergic therapy. PRECEPT data confirmed the associations of higher baseline UPDRS scores and full‐time employment with shorter time to requiring treatment. Any clinical trial using the end point of time to disability requiring dopaminergic therapy should ensure that groups are well balanced with respect to baseline UPDRS scores and the proportion of subjects employed full time and should consider including these variables as covariates in the statistical model for primary analysis of treatment effects. We suspect that individuals employed full time may have a lower threshold for requiring dopaminergic therapy because of occupational demands. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Connie Marras MD, PhD</name><affiliations><json:string>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada</json:string><json:string>University of Toronto, Toronto, Ontario, Canada</json:string></affiliations></json:item><json:item><name>Michael P. McDermott PhD</name><affiliations><json:string>University of Rochester, Rochester, New York, USA</json:string></affiliations></json:item><json:item><name>Ken Marek MD</name><affiliations><json:string>Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA</json:string></affiliations></json:item><json:item><name>Paula Rochon MD, MPH</name><affiliations><json:string>University of Toronto, Toronto, Ontario, Canada</json:string><json:string>Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada</json:string><json:string>Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada</json:string></affiliations></json:item><json:item><name>Gary Naglie MD</name><affiliations><json:string>University of Toronto, Toronto, Ontario, Canada</json:string><json:string>Toronto Rehabilitation Institute, Toronto, Ontario Canada</json:string><json:string>Division of Clinical Decision Making and Health Care, Toronto General Research Institute, Toronto, Ontario, Canada</json:string><json:string>University Health Network, Divisions of General Internal Medicine and Geriatrics Program, Toronto, Ontario, Canada</json:string></affiliations></json:item><json:item><name>Caroline M. Tanner MD, PhD</name><affiliations><json:string>The Parkinson's Institute, Sunnyvale, California, USA</json:string></affiliations></json:item><json:item><name>Alice Rudolph PhD</name><affiliations><json:string>University of Rochester, Rochester, New York, USA</json:string></affiliations></json:item><json:item><name>Ira Shoulson MD</name><affiliations><json:string>University of Rochester, Rochester, New York, USA</json:string></affiliations></json:item><json:item><name>Anthony E. Lang MD</name><affiliations><json:string>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada</json:string><json:string>University of Toronto, Toronto, Ontario, Canada</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>prognosis</value></json:item></subject><articleId><json:string>MDS23581</json:string></articleId><language><json:string>eng</json:string></language><abstract>The rate of progression of Parkinson's disease (PD) is highly variable. Knowledge of factors associated with disease milestones and commonly used research outcome measures helps with patient counseling and guides the design and interpretation of clinical studies. The objective of the study was to identify prognostic factors for time to acquiring disability requiring dopaminergic therapy that are reproducible within 2 large prospectively followed cohorts. Potential prognostic factors were identified using data from the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) trial, and their reproducibility was examined using data from the Parkinson Research Examination of CEP‐1347 trial (PRECEPT). In multivariable analyses of the DATATOP cohort, higher baseline Unified Parkinson's Disease Rating Scale (UPDRS) scores, full‐time employment, a lesser smoking history, and onset on the left side were associated with a shorter time to disability requiring dopaminergic therapy. PRECEPT data confirmed the associations of higher baseline UPDRS scores and full‐time employment with shorter time to requiring treatment. Any clinical trial using the end point of time to disability requiring dopaminergic therapy should ensure that groups are well balanced with respect to baseline UPDRS scores and the proportion of subjects employed full time and should consider including these variables as covariates in the statistical model for primary analysis of treatment effects. We suspect that individuals employed full time may have a lower threshold for requiring dopaminergic therapy because of occupational demands. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>6.318</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>2</keywordCount><abstractCharCount>1666</abstractCharCount><pdfWordCount>3510</pdfWordCount><pdfCharCount>23991</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>234</abstractWordCount></qualityIndicators><title>Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts</title><corporate><json:item><name>on behalf of the Parkinson Study Group DATATOP and PRECEPT investigators</name></json:item></corporate><genre><json:string>article</json:string></genre><host><volume>26</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>6</total><last>613</last><first>608</first></pages><issn><json:string>0885-3185</json:string></issn><issue>4</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23581</json:string></doi><id>86D7BA3E8F5196138DC85683158DA557FCFD657F</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/86D7BA3E8F5196138DC85683158DA557FCFD657F/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/86D7BA3E8F5196138DC85683158DA557FCFD657F/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/86D7BA3E8F5196138DC85683158DA557FCFD657F/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><notesStmt><note type="content">*Relevant conflict of interest: Nothing to report.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts</title><author><orgName>on behalf of the Parkinson Study Group DATATOP and PRECEPT investigators</orgName></author><author><persName><forename type="first">Connie</forename><surname>Marras</surname></persName><roleName type="degree">MD, PhD</roleName><note type="correspondence"><p>Correspondence: Connie Marras, Toronto Western Hospital Movement Disorders Centre, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada</p></note><affiliation>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada</affiliation><affiliation>University of Toronto, Toronto, Ontario, Canada</affiliation></author><author><persName><forename type="first">Michael P.</forename><surname>McDermott</surname></persName><roleName type="degree">PhD</roleName><affiliation>University of Rochester, Rochester, New York, USA</affiliation></author><author><persName><forename type="first">Ken</forename><surname>Marek</surname></persName><roleName type="degree">MD</roleName><affiliation>Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA</affiliation></author><author><persName><forename type="first">Paula</forename><surname>Rochon</surname></persName><roleName type="degree">MD, MPH</roleName><affiliation>University of Toronto, Toronto, Ontario, Canada</affiliation><affiliation>Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada</affiliation><affiliation>Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada</affiliation></author><author><persName><forename type="first">Gary</forename><surname>Naglie</surname></persName><roleName type="degree">MD</roleName><affiliation>University of Toronto, Toronto, Ontario, Canada</affiliation><affiliation>Toronto Rehabilitation Institute, Toronto, Ontario Canada</affiliation><affiliation>Division of Clinical Decision Making and Health Care, Toronto General Research Institute, Toronto, Ontario, Canada</affiliation><affiliation>University Health Network, Divisions of General Internal Medicine and Geriatrics Program, Toronto, Ontario, Canada</affiliation></author><author><persName><forename type="first">Caroline M.</forename><surname>Tanner</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation></author><author><persName><forename type="first">Alice</forename><surname>Rudolph</surname></persName><roleName type="degree">PhD</roleName><affiliation>University of Rochester, Rochester, New York, USA</affiliation></author><author><persName><forename type="first">Ira</forename><surname>Shoulson</surname></persName><roleName type="degree">MD</roleName><affiliation>University of Rochester, Rochester, New York, USA</affiliation></author><author><persName><forename type="first">Anthony E.</forename><surname>Lang</surname></persName><roleName type="degree">MD</roleName><affiliation>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada</affiliation><affiliation>University of Toronto, Toronto, Ontario, Canada</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-03"></date><biblScope unit="volume">26</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="608">608</biblScope><biblScope unit="page" to="613">613</biblScope></imprint></monogr><idno type="istex">86D7BA3E8F5196138DC85683158DA557FCFD657F</idno><idno type="DOI">10.1002/mds.23581</idno><idno type="ArticleID">MDS23581</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The rate of progression of Parkinson's disease (PD) is highly variable. Knowledge of factors associated with disease milestones and commonly used research outcome measures helps with patient counseling and guides the design and interpretation of clinical studies. The objective of the study was to identify prognostic factors for time to acquiring disability requiring dopaminergic therapy that are reproducible within 2 large prospectively followed cohorts. Potential prognostic factors were identified using data from the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) trial, and their reproducibility was examined using data from the Parkinson Research Examination of CEP‐1347 trial (PRECEPT). In multivariable analyses of the DATATOP cohort, higher baseline Unified Parkinson's Disease Rating Scale (UPDRS) scores, full‐time employment, a lesser smoking history, and onset on the left side were associated with a shorter time to disability requiring dopaminergic therapy. PRECEPT data confirmed the associations of higher baseline UPDRS scores and full‐time employment with shorter time to requiring treatment. Any clinical trial using the end point of time to disability requiring dopaminergic therapy should ensure that groups are well balanced with respect to baseline UPDRS scores and the proportion of subjects employed full time and should consider including these variables as covariates in the statistical model for primary analysis of treatment effects. We suspect that individuals employed full time may have a lower threshold for requiring dopaminergic therapy because of occupational demands. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>prognosis</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-05-10">Received</change><change when="2010-11-16">Registration</change><change when="2011-03">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/86D7BA3E8F5196138DC85683158DA557FCFD657F/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="40"><doi origin="wiley" registered="yes">10.1002/mds.v26.4</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">4</numbering></numberingGroup><coverDate startDate="2011-03">March 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="90" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23581</doi><idGroup><id type="unit" value="MDS23581"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2010-05-10"></event><event type="manuscriptRevised" date="2010-11-08"></event><event type="manuscriptAccepted" date="2010-11-16"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.5.2 mode:FullText" date="2011-07-19"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-02-01"></event><event type="publishedOnlineFinalForm" date="2011-04-19"></event><event type="firstOnline" date="2011-02-01"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">608</numbering><numbering type="pageLast">613</numbering></numberingGroup><correspondenceTo>Connie Marras, Toronto Western Hospital Movement Disorders Centre, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23581.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="18"></count><count type="wordTotal" number="7445"></count></countGroup><titleGroup><title type="main" xml:lang="en">Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts<link href="#fn1"></link></title><title type="short" xml:lang="en">Time to Requiring Treatment in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Connie</givenNames><familyName>Marras</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>connie.marras@utoronto.ca</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Michael P.</givenNames><familyName>McDermott</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Ken</givenNames><familyName>Marek</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af2 #af5 #af6"><personName><givenNames>Paula</givenNames><familyName>Rochon</familyName><degrees>MD, MPH</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af2 #af7 #af8 #af9"><personName><givenNames>Gary</givenNames><familyName>Naglie</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af10"><personName><givenNames>Caroline M.</givenNames><familyName>Tanner</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Alice</givenNames><familyName>Rudolph</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Ira</givenNames><familyName>Shoulson</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Anthony E.</givenNames><familyName>Lang</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af1 #af2"><groupName>on behalf of the Parkinson Study Group DATATOP and PRECEPT investigators</groupName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="CA" type="organization"><unparsedAffiliation>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="CA" type="organization"><unparsedAffiliation>University of Toronto, Toronto, Ontario, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>University of Rochester, Rochester, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="CA" type="organization"><unparsedAffiliation>Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="CA" type="organization"><unparsedAffiliation>Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="CA" type="organization"><unparsedAffiliation>Toronto Rehabilitation Institute, Toronto, Ontario Canada</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="CA" type="organization"><unparsedAffiliation>Division of Clinical Decision Making and Health Care, Toronto General Research Institute, Toronto, Ontario, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af9" countryCode="CA" type="organization"><unparsedAffiliation>University Health Network, Divisions of General Internal Medicine and Geriatrics Program, Toronto, Ontario, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af10" countryCode="US" type="organization"><unparsedAffiliation>The Parkinson's Institute, Sunnyvale, California, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">prognosis</keyword></keywordGroup><supportingInformation><p> See Appendix online for the full list of DATATOP and PRECEPT investigators. </p><supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds23581:MDS_23581_sm_appendix"></mediaResource><caption>APPENDIX: DATATOP Investigators and Coordinators</caption></supportingInfoItem><supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds23581:MDS_23581_sm_authorroles"></mediaResource><caption>Author Roles and Disclosures</caption></supportingInfoItem></supportingInformation><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The rate of progression of Parkinson's disease (PD) is highly variable. Knowledge of factors associated with disease milestones and commonly used research outcome measures helps with patient counseling and guides the design and interpretation of clinical studies. The objective of the study was to identify prognostic factors for time to acquiring disability requiring dopaminergic therapy that are reproducible within 2 large prospectively followed cohorts. Potential prognostic factors were identified using data from the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) trial, and their reproducibility was examined using data from the Parkinson Research Examination of CEP‐1347 trial (PRECEPT). In multivariable analyses of the DATATOP cohort, higher baseline Unified Parkinson's Disease Rating Scale (UPDRS) scores, full‐time employment, a lesser smoking history, and onset on the left side were associated with a shorter time to disability requiring dopaminergic therapy. PRECEPT data confirmed the associations of higher baseline UPDRS scores and full‐time employment with shorter time to requiring treatment. Any clinical trial using the end point of time to disability requiring dopaminergic therapy should ensure that groups are well balanced with respect to baseline UPDRS scores and the proportion of subjects employed full time and should consider including these variables as covariates in the statistical model for primary analysis of treatment effects. We suspect that individuals employed full time may have a lower threshold for requiring dopaminergic therapy because of occupational demands. © 2011 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p><b>Relevant conflict of interest</b>: Nothing to report.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Time to Requiring Treatment in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts</title></titleInfo><name type="personal"><namePart type="given">Connie</namePart><namePart type="family">Marras</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada</affiliation><affiliation>University of Toronto, Toronto, Ontario, Canada</affiliation><description>Correspondence: Connie Marras, Toronto Western Hospital Movement Disorders Centre, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michael P.</namePart><namePart type="family">McDermott</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>University of Rochester, Rochester, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ken</namePart><namePart type="family">Marek</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Paula</namePart><namePart type="family">Rochon</namePart><namePart type="termsOfAddress">MD, MPH</namePart><affiliation>University of Toronto, Toronto, Ontario, Canada</affiliation><affiliation>Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada</affiliation><affiliation>Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gary</namePart><namePart type="family">Naglie</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>University of Toronto, Toronto, Ontario, Canada</affiliation><affiliation>Toronto Rehabilitation Institute, Toronto, Ontario Canada</affiliation><affiliation>Division of Clinical Decision Making and Health Care, Toronto General Research Institute, Toronto, Ontario, Canada</affiliation><affiliation>University Health Network, Divisions of General Internal Medicine and Geriatrics Program, Toronto, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Caroline M.</namePart><namePart type="family">Tanner</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alice</namePart><namePart type="family">Rudolph</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>University of Rochester, Rochester, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ira</namePart><namePart type="family">Shoulson</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>University of Rochester, Rochester, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anthony E.</namePart><namePart type="family">Lang</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada</affiliation><affiliation>University of Toronto, Toronto, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="corporate"><namePart>on behalf of the Parkinson Study Group DATATOP and PRECEPT investigators</namePart><description>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, CanadaUniversity of Toronto, Toronto, Ontario, CanadaUniversity of Rochester, Rochester, New York, USAInstitute for Neurodegenerative Disorders, New Haven, Connecticut, USAWomen's College Research Institute, Women's College Hospital, Toronto, Ontario, CanadaInstitute for Clinical Evaluative Sciences, Toronto, Ontario, CanadaToronto Rehabilitation Institute, Toronto, Ontario CanadaDivision of Clinical Decision Making and Health Care, Toronto General Research Institute, Toronto, Ontario, CanadaUniversity Health Network, Divisions of General Internal Medicine and Geriatrics Program, Toronto, Ontario, CanadaThe Parkinson's Institute, Sunnyvale, California, USA</description></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-03</dateIssued><dateCaptured encoding="w3cdtf">2010-05-10</dateCaptured><dateValid encoding="w3cdtf">2010-11-16</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">3</extent><extent unit="references">18</extent><extent unit="words">7445</extent></physicalDescription><abstract lang="en">The rate of progression of Parkinson's disease (PD) is highly variable. Knowledge of factors associated with disease milestones and commonly used research outcome measures helps with patient counseling and guides the design and interpretation of clinical studies. The objective of the study was to identify prognostic factors for time to acquiring disability requiring dopaminergic therapy that are reproducible within 2 large prospectively followed cohorts. Potential prognostic factors were identified using data from the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) trial, and their reproducibility was examined using data from the Parkinson Research Examination of CEP‐1347 trial (PRECEPT). In multivariable analyses of the DATATOP cohort, higher baseline Unified Parkinson's Disease Rating Scale (UPDRS) scores, full‐time employment, a lesser smoking history, and onset on the left side were associated with a shorter time to disability requiring dopaminergic therapy. PRECEPT data confirmed the associations of higher baseline UPDRS scores and full‐time employment with shorter time to requiring treatment. Any clinical trial using the end point of time to disability requiring dopaminergic therapy should ensure that groups are well balanced with respect to baseline UPDRS scores and the proportion of subjects employed full time and should consider including these variables as covariates in the statistical model for primary analysis of treatment effects. We suspect that individuals employed full time may have a lower threshold for requiring dopaminergic therapy because of occupational demands. © 2011 Movement Disorder Society</abstract><note type="content">*Relevant conflict of interest: Nothing to report.</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>prognosis</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><note type="content"> See Appendix online for the full list of DATATOP and PRECEPT investigators.Supporting Info Item: APPENDIX: DATATOP Investigators and Coordinators - Author Roles and Disclosures - </note><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>608</start><end>613</end><total>6</total></extent></part></relatedItem><identifier type="istex">86D7BA3E8F5196138DC85683158DA557FCFD657F</identifier><identifier type="DOI">10.1002/mds.23581</identifier><identifier type="ArticleID">MDS23581</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000275 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000275 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:86D7BA3E8F5196138DC85683158DA557FCFD657F
|texte= Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts
}}
| This area was generated with Dilib version V0.6.23. |  |